Cargando…
Neuroleptic malignant syndrome with haloperidol and quetiapine treatment in a schizophrenia patient: A case report and 1 year follow up
INTRODUCTION: Neuroleptic malignant syndrome is a rare but also life-threatening adverse reaction associated with mostly antipsychotic use. It is mostly related with the administration of D2 dopamine receptor-blocking antipsychotics or sudden discontinuation of antiparkinsonian drugs. OBJECTIVES: In...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479129/ http://dx.doi.org/10.1192/j.eurpsy.2023.2133 |
_version_ | 1785101506554363904 |
---|---|
author | Alioglu Karayilan, F. Yildiz, B. Ak, I. |
author_facet | Alioglu Karayilan, F. Yildiz, B. Ak, I. |
author_sort | Alioglu Karayilan, F. |
collection | PubMed |
description | INTRODUCTION: Neuroleptic malignant syndrome is a rare but also life-threatening adverse reaction associated with mostly antipsychotic use. It is mostly related with the administration of D2 dopamine receptor-blocking antipsychotics or sudden discontinuation of antiparkinsonian drugs. OBJECTIVES: In this article, we present a 55-year-old male patient diagnosed with schizophrenia who was admitted to the emergency department with acute onset confusion and fever. He had been on haloperidol and quetiapine treatment for several years. METHODS: His Creatine kinase (CK) levels were elevated (2928 - 11462 U/l within 1 day. U/l). She was admitted to the intensive care unit with an initial diagnosis of NMS. The patient’s all antipsychotic treatment was discontinued. RESULTS: At a follow-up examination after 6 days, myoglobin, CK, and leukocyte values were noted to start decreasing. The rigidity and altered mental status improved after 6 days. After 9 days he was discharged. He was admitted to the psychiatry outpatient clinic. He was suffering from auditory hallucinations therefore the antipsychotic treatment has been started and it was planned to reach the target dose of 10mg olanzapine PO by increasing the weekly dose to 2.5 mg. However, due to the increase in the patient’s auditory hallucinations, the treatment was rearranged and the target dose of 15mg was reached. After that, the patient’s positive symptoms regressed significantly. The patient has been on 15 mg olanzapine treatment for the last 1 year with no positive symptoms. CONCLUSIONS: What is the most appropriate treatment choice after NMS? There is no easy, single answer to this question. Although we were aware that there have been reported NMS cases with olanzapine use for this patient it was chosen since it is one of the second-generation antipsychotics that the patient did not use by examining the treatment history. This case shows that this syndrome may develop even after a long and stable neuroleptic treatment and the patient may continue to benefit from different antipsychotic treatments. DISCLOSURE OF INTEREST: None Declared |
format | Online Article Text |
id | pubmed-10479129 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-104791292023-09-06 Neuroleptic malignant syndrome with haloperidol and quetiapine treatment in a schizophrenia patient: A case report and 1 year follow up Alioglu Karayilan, F. Yildiz, B. Ak, I. Eur Psychiatry Abstract INTRODUCTION: Neuroleptic malignant syndrome is a rare but also life-threatening adverse reaction associated with mostly antipsychotic use. It is mostly related with the administration of D2 dopamine receptor-blocking antipsychotics or sudden discontinuation of antiparkinsonian drugs. OBJECTIVES: In this article, we present a 55-year-old male patient diagnosed with schizophrenia who was admitted to the emergency department with acute onset confusion and fever. He had been on haloperidol and quetiapine treatment for several years. METHODS: His Creatine kinase (CK) levels were elevated (2928 - 11462 U/l within 1 day. U/l). She was admitted to the intensive care unit with an initial diagnosis of NMS. The patient’s all antipsychotic treatment was discontinued. RESULTS: At a follow-up examination after 6 days, myoglobin, CK, and leukocyte values were noted to start decreasing. The rigidity and altered mental status improved after 6 days. After 9 days he was discharged. He was admitted to the psychiatry outpatient clinic. He was suffering from auditory hallucinations therefore the antipsychotic treatment has been started and it was planned to reach the target dose of 10mg olanzapine PO by increasing the weekly dose to 2.5 mg. However, due to the increase in the patient’s auditory hallucinations, the treatment was rearranged and the target dose of 15mg was reached. After that, the patient’s positive symptoms regressed significantly. The patient has been on 15 mg olanzapine treatment for the last 1 year with no positive symptoms. CONCLUSIONS: What is the most appropriate treatment choice after NMS? There is no easy, single answer to this question. Although we were aware that there have been reported NMS cases with olanzapine use for this patient it was chosen since it is one of the second-generation antipsychotics that the patient did not use by examining the treatment history. This case shows that this syndrome may develop even after a long and stable neuroleptic treatment and the patient may continue to benefit from different antipsychotic treatments. DISCLOSURE OF INTEREST: None Declared Cambridge University Press 2023-07-19 /pmc/articles/PMC10479129/ http://dx.doi.org/10.1192/j.eurpsy.2023.2133 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Alioglu Karayilan, F. Yildiz, B. Ak, I. Neuroleptic malignant syndrome with haloperidol and quetiapine treatment in a schizophrenia patient: A case report and 1 year follow up |
title | Neuroleptic malignant syndrome with haloperidol and quetiapine treatment in a schizophrenia patient: A case report and 1 year follow up |
title_full | Neuroleptic malignant syndrome with haloperidol and quetiapine treatment in a schizophrenia patient: A case report and 1 year follow up |
title_fullStr | Neuroleptic malignant syndrome with haloperidol and quetiapine treatment in a schizophrenia patient: A case report and 1 year follow up |
title_full_unstemmed | Neuroleptic malignant syndrome with haloperidol and quetiapine treatment in a schizophrenia patient: A case report and 1 year follow up |
title_short | Neuroleptic malignant syndrome with haloperidol and quetiapine treatment in a schizophrenia patient: A case report and 1 year follow up |
title_sort | neuroleptic malignant syndrome with haloperidol and quetiapine treatment in a schizophrenia patient: a case report and 1 year follow up |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479129/ http://dx.doi.org/10.1192/j.eurpsy.2023.2133 |
work_keys_str_mv | AT alioglukarayilanf neurolepticmalignantsyndromewithhaloperidolandquetiapinetreatmentinaschizophreniapatientacasereportand1yearfollowup AT yildizb neurolepticmalignantsyndromewithhaloperidolandquetiapinetreatmentinaschizophreniapatientacasereportand1yearfollowup AT aki neurolepticmalignantsyndromewithhaloperidolandquetiapinetreatmentinaschizophreniapatientacasereportand1yearfollowup |